BB Biotech AG publishes its interim report, announcing a net profit of CHF 175 million for the third quarter of 2026 and CHF 605 million for the first nine months.

The investment company's net asset value (NAV) saw a 5.6% return in CHF during Q3, with the share price returning 6.5% in CHF. The report also highlighted clinical and regulatory advancements within its portfolio and the reinvestment of approximately CHF 280 million from two completed M&A transactions.